Clinical trials: Stroke/TIA
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Safety and Efficacy of CG-BM1 in Ischemic Stroke
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
- Trial name
- NCT07896941
- Testing
- single infusion, 1.0 × 10^6 cells/kg, single infusion, 2.0 × 10^6 cells/kg, single infusion, 3.0 × 10^6 cells/kg
- Where
- China
- Volunteers
- 87 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
MCA - Middle Cerebral Artery Dissection
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.
- Trial name
- NCT02953405
- Testing
- Clopidogrel
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Carotid Artery Diseases, Stroke
Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)
The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be…
- Conditions
- Carotid Artery Diseases, Stroke, Cerebral Arteriosclerosis
- Trial name
- BEACH (NCT00316108)
- Testing
- WALLSTENT® Endoprosthesis™
- Where
- 50 sites in United States
- Volunteers
- 747 people
- Sponsor
- Boston Scientific Corporation
Hypertension, Ischemic Stroke
Fimasartan Blood Pressure Lowering After Acute Stroke
This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients.
- Conditions
- Hypertension, Ischemic Stroke, Transient Ischemic Attack
- Trial name
- FABULOUS (NCT03231293)
- Where
- 27 sites in South Korea
- Volunteers
- 1,035 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Suspected Arrhythmia, Palpitations
This Exploratory Medical Device Study Evaluated the Arrhythmia Diagnostic Yield of MEMO Patch V2, a Wearable Patch-type Electrocardiographic Monitor, in Adults With Suspected Arrhythmia Who Presented With Symptoms Such as Palpitations or Dizziness, or Who Had Cryptogenic Ischemic Stroke or Transient
This exploratory medical device study evaluated the arrhythmia diagnostic yield of MEMO Patch V2, a wearable patch-type electrocardiographic monitor, in adults with suspected arrhythmia who presented with symptoms such as…
- Conditions
- Suspected Arrhythmia, Palpitations, Dizziness, Cryptogenic Ischemic Stroke
- Trial name
- NCT07722026
- Testing
- MEMO Patch V2, 24-Hour Holter Monitor
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- HUINNO Co., Ltd
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Stenosis, Bleed Intracranial
Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study
This prospective observational post-market clinical study will collect data in the United States to primarily support the re-launch of the re-designed Beacon Tip Sizing Catheter and Slip-Catheter Beacon Tip Catheter \& Shuttle…
- Conditions
- Stenosis, Bleed Intracranial, Stroke, TIA
- Trial name
- NCT06986954
- Testing
- Beacon Tip Catheters
- Where
- United States
- Volunteers
- 816 people
- Sponsor
- Cook Research Incorporated
Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: an acute stroke due to a blood clot that formed outside the…
- Conditions
- Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
- Trial name
- OCEANIC-STROKE (NCT05686070)
- Testing
- Asundexian (BAY2433334)
- Where
- 741 sites in United States, Argentina and 35 more
- Volunteers
- 12,327 people
- Sponsor
- Bayer
Left Atrial Appendage Exclusion
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.
- Trial name
- EXCLUDE (NCT00779857)
- Testing
- AtriCure LAA Exclusion System
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- AtriCure, Inc.
Cryptogenic Symptomatic Transient Ischemic Attack, Cryptogenic Ischemic Stroke
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take…
- Trial name
- CRYSTAL-AF (NCT00924638)
- Testing
- Reveal® XT Insertable Cardiac Monitor
- Where
- 55 sites in United States, Austria and 12 more
- Volunteers
- 447 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Stroke, Transient Ischemic Attack
The Recurrence Study
The primarily goal of the research is to better understand progression of disease in patients who present with an acute stroke to the Hamad General Hospital (HGH) stroke and Transient Ischemic Attack (TIA) clinic.
- Trial name
- NCT03244215
- Testing
- Corneal Confocal Imaging, Magnetic resonance Imaging, Blood sample
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Cardiovascular Disease
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.
- Trial name
- SPARCL (NCT00147602)
- Testing
- atorvastatin
- Where
- 130 sites in Australia, Austria and 23 more
- Volunteers
- 4,732 people
- Sponsor
- Pfizer
PFO, Stroke
PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness
The primary object of this study is to demonstrate the continued safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or…
- Conditions
- PFO, Stroke, Transient Ischemic Attack, Migraine
- Trial name
- Paradigm IV (NCT00529945)
- Testing
- PFx Closure System
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cierra
Ischemic Stroke, Transient Ischemic Attack
Trial of a Secondary Stroke Prevention Program
The purpose of this study is to determine whether an outpatient program can reduce the risk of recurrent stroke.
- Trial name
- NCT01071408
- Testing
- Stroke prevention care program
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sepulveda Research Corporation
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Atrial Fibrillation, AFib
Stroke Feasibility Study
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage.
- Trial name
- NCT01997905
- Testing
- AtriClip LAA Exclusion Device
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- AtriCure, Inc.
Carotid Artery Disease, Stroke
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA)…
- Conditions
- Carotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
- Trial name
- CANOPY (NCT01445613)
- Testing
- RX Acculink Carotid Stent System (RX Acculink)
- Where
- United States
- Volunteers
- 1,203 people
- Sponsor
- Abbott Medical Devices